Results from the latest trial comparing nonsurgical implantation of a prosthetic transcatheter aortic valve replacement, or TAVR, with traditional surgical aortic valve replacement have raised the possibility that the new method could be used for a broader range of patients.
But shifting to wider TAVR device use could hurt hospitals financially because of their high cost.
At the American College of Cardiology's annual scientific session in Washington, medical devicemaker Medtronic reported results from the high-risk patient group included in the U.S. Pivotal trial of its CoreValve TAVR device. Session co-chair Dr. Prediman Shah, director of the Atherosclerosis Prevention and Treatment Center at Los Angeles' Cedars-Sinai Medical Center, said in a March 18 telebriefing that TAVR would someday replace surgery as the preferred method for aortic valve replacement.
“It's going to be very hard to tell a patient, if they need an aortic valve, that surgery is their best option,” he said in a March 19 report in Cardiology News.